“The AstraZeneca COVID-19 vaccine (together with Covishield) continues to have a optimistic benefit-risk profile, with large potential to forestall infections and cut back deaths internationally,” the WHO’s international advisory committee on vaccine security stated in an announcement.
Covishield refers to AstraZeneca vaccine produced by Serum Institute of India.
The WHO panel of 12 unbiased consultants, who met nearly on Tuesday and on Thursday, reviewed security information from Europe, the UK, India, and WHO’s international database.
“Whereas very uncommon and distinctive thromboembolic occasions together with thrombocytopenia, comparable to cerebral venous sinus thrombosis (CVST), have additionally been reported following vaccination with the AstraZeneca COVID-19 vaccine in Europe, it isn’t sure that they’ve been brought on by vaccination,” it stated.
Europe was pushing to get its vaccination drive again on observe on Friday after European and British regulators had additionally stated the advantages of AstraZeneca’s shot outweighed dangers.